207 related articles for article (PubMed ID: 38555305)
1. Myeloid-derived suppressor cell mitochondrial fitness governs chemotherapeutic efficacy in hematologic malignancies.
Daneshmandi S; Choi JE; Yan Q; MacDonald CR; Pandey M; Goruganthu M; Roberts N; Singh PK; Higashi RM; Lane AN; Fan TW; Wang J; McCarthy PL; Repasky EA; Mohammadpour H
Nat Commun; 2024 Mar; 15(1):2803. PubMed ID: 38555305
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppressive activity enhances central carbon metabolism and bioenergetics in myeloid-derived suppressor cells in vitro models.
Hammami I; Chen J; Murschel F; Bronte V; De Crescenzo G; Jolicoeur M
BMC Cell Biol; 2012 Jul; 13():18. PubMed ID: 22762146
[TBL] [Abstract][Full Text] [Related]
3. β2 adrenergic receptor-mediated signaling regulates the immunosuppressive potential of myeloid-derived suppressor cells.
Mohammadpour H; MacDonald CR; Qiao G; Chen M; Dong B; Hylander BL; McCarthy PL; Abrams SI; Repasky EA
J Clin Invest; 2019 Dec; 129(12):5537-5552. PubMed ID: 31566578
[TBL] [Abstract][Full Text] [Related]
4. High monocytic MDSC signature predicts multi-drug resistance and cancer relapse in non-Hodgkin lymphoma patients treated with R-CHOP.
Dhar S; Chakravarti M; Ganguly N; Saha A; Dasgupta S; Bera S; Sarkar A; Roy K; Das J; Bhuniya A; Ghosh S; Sarkar M; Hajra S; Banerjee S; Pal C; Saha B; Mukherjee KK; Baral R; Bose A
Front Immunol; 2023; 14():1303959. PubMed ID: 38304256
[TBL] [Abstract][Full Text] [Related]
5. Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHD.
Koehn BH; Saha A; McDonald-Hyman C; Loschi M; Thangavelu G; Ma L; Zaiken M; Dysthe J; Krepps W; Panthera J; Hippen K; Jameson SC; Miller JS; Cooper MA; Farady CJ; Iwawaki T; Ting JP; Serody JS; Murphy WJ; Hill GR; Murray PJ; Bronte V; Munn DH; Zeiser R; Blazar BR
Blood; 2019 Nov; 134(19):1670-1682. PubMed ID: 31533918
[TBL] [Abstract][Full Text] [Related]
6. β2-adrenergic receptor signaling regulates metabolic pathways critical to myeloid-derived suppressor cell function within the TME.
Mohammadpour H; MacDonald CR; McCarthy PL; Abrams SI; Repasky EA
Cell Rep; 2021 Oct; 37(4):109883. PubMed ID: 34706232
[TBL] [Abstract][Full Text] [Related]
7. The role of myeloid-derived suppressor cells in hematologic malignancies.
Gunes EG; Rosen ST; Querfeld C
Curr Opin Oncol; 2020 Sep; 32(5):518-526. PubMed ID: 32675593
[TBL] [Abstract][Full Text] [Related]
8. IRAK1-regulated IFN-γ signaling induces MDSC to facilitate immune evasion in FGFR1-driven hematological malignancies.
Cai B; Liu Y; Chong Y; Zhang H; Matsunaga A; Fang X; Pacholczyk R; Zhou G; Cowell JK; Hu T
Mol Cancer; 2021 Dec; 20(1):165. PubMed ID: 34906138
[TBL] [Abstract][Full Text] [Related]
9. Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells.
Deng Y; Cheng J; Fu B; Liu W; Chen G; Zhang Q; Yang Y
Oncogene; 2017 Feb; 36(8):1090-1101. PubMed ID: 27593937
[TBL] [Abstract][Full Text] [Related]
10. VISTA promotes the metabolism and differentiation of myeloid-derived suppressor cells by STAT3 and polyamine-dependent mechanisms.
Zhang K; Zakeri A; Alban T; Dong J; Ta HM; Zalavadia AH; Branicky A; Zhao H; Juric I; Husich H; Parthasarathy PB; Rupani A; Drazba JA; Chakraborty AA; Ching-Cheng Huang S; Chan T; Avril S; Wang LL
Cell Rep; 2024 Jan; 43(1):113661. PubMed ID: 38175754
[TBL] [Abstract][Full Text] [Related]
11. ISG15 deficiency features a complex cellular phenotype that responds to treatment with itaconate and derivatives.
Waqas SF; Sohail A; Nguyen AHH; Usman A; Ludwig T; Wegner A; Malik MNH; Schuchardt S; Geffers R; Winterhoff M; Merkert S; Martin U; Olmer R; Lachmann N; Pessler F
Clin Transl Med; 2022 Jul; 12(7):e931. PubMed ID: 35842904
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin resistant cancer cells activate myeloid-derived suppressor cells by releasing PGE2.
Rong Y; Yuan CH; Qu Z; Zhou H; Guan Q; Yang N; Leng XH; Bu L; Wu K; Wang FB
Sci Rep; 2016 Apr; 6():23824. PubMed ID: 27032536
[TBL] [Abstract][Full Text] [Related]
13. Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma.
Zhao Q; Huang L; Qin G; Qiao Y; Ren F; Shen C; Wang S; Liu S; Lian J; Wang D; Yu W; Zhang Y
Cancer Lett; 2021 Oct; 518():35-48. PubMed ID: 34139285
[TBL] [Abstract][Full Text] [Related]
14. Blockade of Myd88 signaling by a novel MyD88 inhibitor prevents colitis-associated colorectal cancer development by impairing myeloid-derived suppressor cells.
Wang L; Hu D; Xie B; Xie L
Invest New Drugs; 2022 Jun; 40(3):506-518. PubMed ID: 35089465
[TBL] [Abstract][Full Text] [Related]
15. Autocrine IL6-Mediated Activation of the STAT3-DNMT Axis Silences the TNFα-RIP1 Necroptosis Pathway to Sustain Survival and Accumulation of Myeloid-Derived Suppressor Cells.
Smith AD; Lu C; Payne D; Paschall AV; Klement JD; Redd PS; Ibrahim ML; Yang D; Han Q; Liu Z; Shi H; Hartney TJ; Nayak-Kapoor A; Liu K
Cancer Res; 2020 Aug; 80(15):3145-3156. PubMed ID: 32554751
[TBL] [Abstract][Full Text] [Related]
16. PMN-MDSCs Enhance CTC Metastatic Properties through Reciprocal Interactions via ROS/Notch/Nodal Signaling.
Sprouse ML; Welte T; Boral D; Liu HN; Yin W; Vishnoi M; Goswami-Sewell D; Li L; Pei G; Jia P; Glitza-Oliva IC; Marchetti D
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31003475
[TBL] [Abstract][Full Text] [Related]
17. Expansion of PMN-myeloid derived suppressor cells and their clinical relevance in patients with oral squamous cell carcinoma.
Zhong LM; Liu ZG; Zhou X; Song SH; Weng GY; Wen Y; Liu FB; Cao DL; Liu YF
Oral Oncol; 2019 Aug; 95():157-163. PubMed ID: 31345384
[TBL] [Abstract][Full Text] [Related]
18. Expansion and activation of monocytic-myeloid-derived suppressor cell via STAT3/arginase-I signaling in patients with ankylosing spondylitis.
Liu YF; Zhuang KH; Chen B; Li PW; Zhou X; Jiang H; Zhong LM; Liu FB
Arthritis Res Ther; 2018 Aug; 20(1):168. PubMed ID: 30075733
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting the biogenesis of myeloid-derived suppressor cells enhances immunotherapy efficacy against mammary tumor progression.
Colligan SH; Amitrano AM; Zollo RA; Peresie J; Kramer ED; Morreale B; Barbi J; Singh PK; Yu H; Wang J; Opyrchal M; Sykes DB; Nemeth MJ; Abrams SI
J Clin Invest; 2022 Dec; 132(23):. PubMed ID: 36453551
[TBL] [Abstract][Full Text] [Related]
20. IL-17 inhibits the accumulation of myeloid-derived suppressor cells in breast cancer via activating STAT3.
Ma M; Huang W; Kong D
Int Immunopharmacol; 2018 Jun; 59():148-156. PubMed ID: 29655056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
